Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Inotek Pharmaceuticals Corporation (ITEK) Stock Price

News articles about Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Inotek Pharmaceuticals Corporation earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.9558069195677 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Separately, Zacks Investment Research downgraded Inotek Pharmaceuticals Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Inotek Pharmaceuticals Corporation has a consensus rating of “Hold” and an average target price of $3.80.

Shares of Inotek Pharmaceuticals Corporation (ITEK) traded up $0.15 during mid-day trading on Tuesday, reaching $2.87. The company’s stock had a trading volume of 563,900 shares, compared to its average volume of 1,165,694. Inotek Pharmaceuticals Corporation has a one year low of $0.85 and a one year high of $7.45. The company has a debt-to-equity ratio of 0.97, a quick ratio of 27.63 and a current ratio of 27.63.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Inotek Pharmaceuticals Corporation (ITEK) Stock Price” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://sportsperspectives.com/2017/11/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-inotek-pharmaceuticals-corporation-itek-stock-price.html.

About Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.

Insider Buying and Selling by Quarter for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)

Receive News & Ratings for Inotek Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply